David J Margolis1, Katrina Abuabara2, Ole J Hoffstad3, Joy Wan2, Denise Raimondo4, Warren B Bilker3. 1. Department of Biostatistics and Epidemiology, University of Pennsylvania Perelman School of Medicine, Philadelphia2Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia. 2. Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia. 3. Department of Biostatistics and Epidemiology, University of Pennsylvania Perelman School of Medicine, Philadelphia. 4. Valeant Pharmaceuticals International, Bridgewater, New Jersey.
Abstract
IMPORTANCE: A black box warning describes a potential risk of malignancy associated with topical use of pimecrolimus to treat atopic dermatitis due to its similarity to oral calcineurin inhibitors used in solid-organ transplantation and spontaneous reporting of malignancies, including lymphomas and cutaneous malignancies. OBJECTIVE: To evaluate the risk of malignancy in a postmarketing study of children exposed to pimecrolimus. DESIGN, SETTING, AND PARTICIPANTS: A longitudinal cohort study among a nationwide ongoing long-term cohort of children enrolled in the Pediatric Eczema Elective Registry (PEER) who had a history of atopic dermatitis and pimecrolimus use with data available up through May 2014. MAIN OUTCOMES AND MEASURES: Reports of malignancy among those in the PEER compared with expected rates from the Surveillance, Epidemiology, and End Results (SEER) program. RESULTS: Overall, 7457 children were enrolled in the PEER, for a total of 26,792 person-years. Children used a mean (SD) of 793 (1356) g of pimecrolimus when enrolled in the study. As of May 2014, five malignancies had been reported. These include 2 leukemias, 1 osteosarcoma, and 2 lymphomas. No skin cancers were reported. The standardized incidence ratio for all malignancies (primary outcome) based on the age-standardized SEER population was 1.2 (95% CI, 0.5-2.8). As secondary analyses, the standardized incidence ratios (based on 2 cases for each) were 2.9 (95% CI, 0.7-11.7) for lymphoma and 2.0 (95% CI, 0.5-8.2) for leukemia. None of these findings were statistically significant. CONCLUSIONS AND RELEVANCE: Based on more than 25,000 person-years of follow-up, it seems unlikely that topical pimecrolimus as it was used in the PEER cohort to treat atopic dermatitis is associated with an increased risk of malignancy.
IMPORTANCE: A black box warning describes a potential risk of malignancy associated with topical use of pimecrolimus to treat atopic dermatitis due to its similarity to oral calcineurin inhibitors used in solid-organ transplantation and spontaneous reporting of malignancies, including lymphomas and cutaneous malignancies. OBJECTIVE: To evaluate the risk of malignancy in a postmarketing study of children exposed to pimecrolimus. DESIGN, SETTING, AND PARTICIPANTS: A longitudinal cohort study among a nationwide ongoing long-term cohort of children enrolled in the Pediatric Eczema Elective Registry (PEER) who had a history of atopic dermatitis and pimecrolimus use with data available up through May 2014. MAIN OUTCOMES AND MEASURES: Reports of malignancy among those in the PEER compared with expected rates from the Surveillance, Epidemiology, and End Results (SEER) program. RESULTS: Overall, 7457 children were enrolled in the PEER, for a total of 26,792 person-years. Children used a mean (SD) of 793 (1356) g of pimecrolimus when enrolled in the study. As of May 2014, five malignancies had been reported. These include 2 leukemias, 1 osteosarcoma, and 2 lymphomas. No skin cancers were reported. The standardized incidence ratio for all malignancies (primary outcome) based on the age-standardized SEER population was 1.2 (95% CI, 0.5-2.8). As secondary analyses, the standardized incidence ratios (based on 2 cases for each) were 2.9 (95% CI, 0.7-11.7) for lymphoma and 2.0 (95% CI, 0.5-8.2) for leukemia. None of these findings were statistically significant. CONCLUSIONS AND RELEVANCE: Based on more than 25,000 person-years of follow-up, it seems unlikely that topical pimecrolimus as it was used in the PEER cohort to treat atopic dermatitis is associated with an increased risk of malignancy.
Authors: Sebastian Schneeweiss; Mike Doherty; Shao Zhu; Donnie Funch; Raymond G Schlienger; Carlos Fernandez-Vidaurre; John D Seeger Journal: Dermatology Date: 2009-03-17 Impact factor: 5.366
Authors: Lawrence F Eichenfield; Wynnis L Tom; Sarah L Chamlin; Steven R Feldman; Jon M Hanifin; Eric L Simpson; Timothy G Berger; James N Bergman; David E Cohen; Kevin D Cooper; Kelly M Cordoro; Dawn M Davis; Alfons Krol; David J Margolis; Amy S Paller; Kathryn Schwarzenberger; Robert A Silverman; Hywel C Williams; Craig A Elmets; Julie Block; Christopher G Harrod; Wendy Smith Begolka; Robert Sidbury Journal: J Am Acad Dermatol Date: 2013-11-27 Impact factor: 11.527
Authors: Roderick J Hay; Nicole E Johns; Hywel C Williams; Ian W Bolliger; Robert P Dellavalle; David J Margolis; Robin Marks; Luigi Naldi; Martin A Weinstock; Sarah K Wulf; Catherine Michaud; Christopher J L Murray; Mohsen Naghavi Journal: J Invest Dermatol Date: 2013-10-28 Impact factor: 8.551
Authors: David J Margolis; Andrea J Apter; Jayanta Gupta; Ole Hoffstad; Maryte Papadopoulos; Linda E Campbell; Aileen Sandilands; W H Irwin McLean; Tim R Rebbeck; Nandita Mitra Journal: J Allergy Clin Immunol Date: 2012-08-27 Impact factor: 10.793
Authors: C A Clarke; L M Morton; C Lynch; R M Pfeiffer; E C Hall; T M Gibson; D D Weisenburger; O Martínez-Maza; S K Hussain; J Yang; E T Chang; E A Engels Journal: Br J Cancer Date: 2013-06-11 Impact factor: 9.075
Authors: J S Song; W B London; E B Hawryluk; D Guo; M Sridharan; D E Fisher; L E Lehmann; C N Duncan; J T Huang Journal: Bone Marrow Transplant Date: 2017-04-03 Impact factor: 5.483
Authors: Joy Wan; Nandita Mitra; Ole J Hoffstad; Joel M Gelfand; Albert C Yan; David J Margolis Journal: J Am Acad Dermatol Date: 2017-08-14 Impact factor: 11.527
Authors: Carolyn Lou; Nandita Mitra; Bradley Wubbenhorst; Kurt D'Andrea; Ole Hoffstad; Brian S Kim; Albert Yan; Andrea L Zaenglein; Zelma Chiesa Fuxench; Katherine L Nathanson; David J Margolis Journal: Ann Allergy Asthma Immunol Date: 2019-09-04 Impact factor: 6.347
Authors: David J Margolis; Nandita Mitra; Brian S Kim; Jamie L Duke; Ron A Berna; Ole J Hoffstad; Jenna R Wasserman; Deborah A Ferriola; Tim L Mosbruger; Bradley S Wubbenhorst; Kathrine L Nathanson; Dimitri S Monos Journal: J Immunol Date: 2021-04-16 Impact factor: 5.422